{"id":2918,"date":"2020-06-04T07:46:03","date_gmt":"2020-06-04T07:46:03","guid":{"rendered":"http:\/\/novalab.bold-themes.com\/demo-02\/?page_id=2918"},"modified":"2026-02-09T13:21:01","modified_gmt":"2026-02-09T12:21:01","slug":"partner","status":"publish","type":"page","link":"https:\/\/impact-acmproject.eu\/mt\/partner\/","title":{"rendered":"Sie\u0127eb\/sie\u0127ba"},"content":{"rendered":"

<\/div><\/div>
<\/div>

PARTENER<\/span><\/span><\/h1>
Sie\u0127eb tal-pro\u0121ett<\/div><\/header>
<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
\"bt_bb_section_bottom_section_coverage_imma\u0121ni\"<\/div><\/section>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/universita_padova.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Universit\u00e0 degli Studi di Padova<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Id-Dipartiment tal-Bijolo\u0121ija tal-Universit\u00e0 ta 'Padova \u0121ie stabbilit f'Ottubru 1983 permezz tal-amalgamazzjoni tal-Istituti tal-Bijolo\u0121ija tal-Annimali, il-Botany, u l-Antropolo\u0121ija, flimkien mal-\u0120nien Botaniku ta' Padova u l-Istazzjon tal-Bijolo\u0121ija Marittima ta 'Chioggia (Venezja).<\/p>\n

B\u0127ala l-koordinatur tal-pro\u0121ett, l-UNIDP ji\u017cgura li l-objettivi tal-pro\u0121ett jallinjaw mat-termini tal-ftehim dwar l-g\u0127otja u l-Konsorzju (CA). Huwa inkarigat li jtejjeb l-istratifikazzjoni ta 'pazjenti ACM, jiddetermina l-kontribut ta' varjanti ta 'sinifikat mhux mag\u0127ruf, u ji\u017cviluppa u jikkaratterizza mudelli preklini\u010bi rilevanti. Barra minn hekk, g\u0127andu r-responsabbilt\u00e0 li jidentifika kwistjonijiet eti\u010bi potenzjali u jsolvihom. L-UNIPD tikkollabora wkoll mill-qrib mas-s\u0127ab biex tivvaluta t-t\u0127assib etiku anti\u010bipat u tindirizza lil dawk emer\u0121enti matul il-kors tal-pro\u0121ett.<\/p>\n

\n<\/div>

<\/div>
is-sit web<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

Consorzio Italbiotec<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

L-organizzazzjoni ewlenija Taljana ming\u0127ajr skop ta\u2019 qlig\u0127 fis-settur tal-bijoteknolo\u0121ija. Dan imexxi l-i\u017cvilupp xjentifiku u t-trasferiment virtu\u017c tal-g\u0127arfien bejn il-komunit\u00e0 tar-ri\u010berka u l-industrija biex tissawwar ekosistema tal-innovazzjoni mill-aktar avvanzata xprunata minn negozji \u0121odda tal-bijoteknolo\u0121ija, kumpaniji, universitajiet fejn il-kooperazzjoni u l-iskambju tal-g\u0127arfien jiskattaw it-tkabbir u l-innovazzjoni sostenibbli. Il-Consorzio Italbiotec, bis-sa\u0127\u0127a tal-g\u0127arfien espert tieg\u0127u, se jkun inkarigat mill-attivitajiet ta\u2019 tixrid, komunikazzjoni, ta\u0127ri\u0121 u sfruttament bl-g\u0127an ta\u2019 livell g\u0127oli li jibni u j\u017comm kultura ta\u2019 komunikazzjoni robusta u effettiva fi \u0127dan il-pro\u0121ett. L-istrate\u0121ija se trawwem ukoll komunit\u00e0 infurmata ta\u2019 partijiet ikkon\u010bernati u atturi multipli interessati u impenjati fis-su\u0121\u0121ett tal-IMPACT u se tikkontribwixxi g\u0127all-a\u0127jar sfruttament tar-ri\u017cultati innovattivi tag\u0127ha.<\/p>\n

\n<\/div>

<\/div>
is-sit web<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/italbiotec.webp\"<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/maastricht.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

L-Universit\u00e0 ta' Maastricht<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

L-Iskola g\u0127all-Mard Kardjovaskulari (CARIM) fl-Universit\u00e0 ta 'Maastricht hija \u010bentru ta' referenza dinji g\u0127all-istudju ta 'mekkani\u017cmi regolatorji tal-\u0121eni fil-kontroll ta' forom \u0121eneti\u010bi u akkwistati ta 'insuffi\u010bjenza tal-qalb. Il-mudelli in vivo u in vitro tal-bniedem jintu\u017caw b\u2019mod regolari biex ji\u0121i studjat il-mard kardijaku tal-bniedem billi ji\u0121u applikati appro\u010b\u010bi bijolo\u0121i\u010bi molekulari u ta\u010b-\u010belloli, kif ukoll fa\u010bilitajiet ta\u2019 skrinjar \u0121enetiku bi fluss g\u0127oli, teknolo\u0121ija eliminatorja trans\u0121ene\/\u0121ene, fenotipar kardijaku, u tekniki tal-imma\u0121ni. Minn bosta snin \u2019l hawn, billi tipprovdi punt ta\u2019 riferiment komplet u globali g\u0127at-tfassil ta\u2019 profili tal-mikroRNAs f\u2019insuffi\u010bjenza tal-qalb, din l-Istituzzjoni titqies b\u0127ala mexxejja fil-qasam epi\u0121enetiku kardijaku madwar id-dinja.<\/p>\n

\n<\/div>

<\/div>
is-sit web<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

AccelBio<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

AccelBio hija organizzazzjoni tal-bijoteknolo\u0121ija ming\u0127ajr skop ta\u2019 qlig\u0127 Portugi\u017ca li tg\u0127aqqad s\u0127ab mill-farma\u010bewtika, il-bijoteknolo\u0121ija, l-akkademja, kapital ta\u2019 riskju u park tal-bijoteknolo\u0121ija.<\/p>\n

AccelBio ju\u017ca appro\u010b\u010bi razzjonali \u0121odda biex jappo\u0121\u0121a pro\u0121etti ta\u2019 skoperta ta\u2019 medi\u010bini translazzjonali f\u2019fa\u017cijiet preklini\u010bi mill-akkademja u n-negozji \u0121odda. L-oqsma ta\u2019 kompetenza tag\u0127hom jinkludu l-mard kardjovaskulari u newrolo\u0121iku, l-immunolo\u0121ija, l-infjammazzjoni, l-infezzjoni, l-onkolo\u0121ija u n-nefrolo\u0121ija, fost l-o\u0127rajn.<\/p>\n

Biex tappo\u0121\u0121ja l-i\u017cvilupp tad-droga, AccelBio tospita pjattaformi tat-teknolo\u0121ija inklu\u017ci organojdi avvanzati, multiomi\u010bi, bijolo\u0121ija komputazzjonali, bijoinformatika u skrining ta 'throughput g\u0127oli. It-tim tat-traduzzjoni huwa ddedikat ukoll biex jappo\u0121\u0121a lir-ri\u010berkaturi u lill-intraprendituri fit-tfassil ta\u2019 pjan direzzjonali minn bank g\u0127al suq, li jsegwi l-a\u0127jar prattiki bba\u017cati fuq l-industrija u li jwassal g\u0127al kandidati tad-droga ta\u2019 kwalit\u00e0 g\u0127olja.<\/p>\n

Fi \u0127dan IMPACT, Accelbio se ju\u017ca l-organoids tal-qalb umani avvanzati b'mod uniku tieg\u0127u biex jippromwovi l-istratifikazzjoni ta 'pazjenti ACM u jikxef u jivvalida mekkani\u017cmi \u0121odda ta' azzjoni, bijomarkaturi u miri terapewti\u010bi g\u0127al din il-marda.<\/p>\n

\n<\/div>

<\/div>
is-sit web<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"logo<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/italfarmaco.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Italfarmaco Spa (ITF)<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Italfarmaco SpA hija kumpanija multinazzjonali Taljana privata li g\u0127andha l-kwartieri \u0121enerali tag\u0127ha f\u2019Milan. Hija topera fl-Italja u barra mill-pajji\u017c fis-setturi farma\u010bewti\u010bi u kimi\u010bi-farma\u010bewti\u010bi permezz ta\u2019 kumpanniji li fihom g\u0127andha interess dirett jew indirett. Italfarmaco twaqqfet fl-1938. Il-Grupp g\u0127andu fa\u010bilitajiet industrijali moderni g\u0127all-produzzjoni ta\u2019 prodotti farma\u010bewti\u010bi ta\u2019 kwalit\u00e0 g\u0127olja u g\u0127andu impenn qawwi g\u0127ar-ri\u010berka, b\u2019mod partikolari fl-oqsma kardjovaskulari, immunolo\u0121i\u010bi u onkolo\u0121i\u010bi.
\nFi \u0127dan l-IMPACT, l-ITF se tkun responsabbli g\u0127all-i\u017cvilupp tal-medi\u010bina u l-assa\u0121\u0121i tal-iskrinjar tal-medi\u010bina u se ta\u0127dem biex tidentifika kimotipi \u0121odda simili g\u0127all-medi\u010bina bil-profil mixtieq.<\/p>\n

\n<\/div>

<\/div>
is-sit web<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

UMC Utrecht<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

I\u010b-\u010aentru Mediku Universitarju ta 'Utrecht (UMC Utrecht) huwa nazzjonalment u internazzjonalment
\n\u010bentru ta 'g\u0127arfien espert rikonoxxut g\u0127all-mard tal-qalb li jintiret. Jospita bijobank kbir ta'
\ndemm u tessut (bijopsija, awtopsja, trapjant) ta' pazjenti b'kardjomijopatija. UMC
\nUtrecht iservi b\u0127ala \u010bentru nazzjonali ta\u2019 riferiment g\u0127al pazjenti b\u2019arritmika
\nkardjomijopatija (ACM) u jikkoordina re\u0121istru nazzjonali ta' pazjenti b'ACM (l-
\nIr-Re\u0121istru tal-ACM tan-Netherlands) li b\u0127alissa jinkludi >2000 pazjent b\u2019ACM u
\nqraba.<\/p>\n

Fi \u0127dan IMPACT, UMC Utrecht se j\u0121ib dejta minn pazjenti inklu\u017ci fl-ACM
\ntirre\u0121istra biex tidentifika gruppi ta\u2019 pazjenti li ju\u017caw l-intelli\u0121enza artifi\u010bjali. L-identifikazzjoni
\nir-raggruppamenti se ji\u0121u vvalidati bejn il-modalitajiet (ECG, imma\u0121ni kardijaka, bijokampjuni). Fi
\nbarra minn hekk, UMC Utrecht se twettaq studji avvanzati dwar l-omika fuq kampjuni tat-tessuti tal-ACM,
\ninklu\u017ci traskriptomika b\u2019nukleu wie\u0127ed, qbid in situ, sekwenzjar tal-RNA u
\nproteomika. Dawn ir-ri\u017cultati sussegwentement se jikkontribwixxu g\u0127al pakketti ta\u2019 \u0127idma o\u0127ra biex jidentifikaw
\nmiri possibbli g\u0127all-medi\u010bina.<\/p>\n

\n<\/div>

<\/div>
is-sit web<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"UMC<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"Lutech\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Soluzzjonijiet Avvanzati Lutech SPA (LUTECH)<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Lutech Advanced Solutions jispikka b\u0127ala fornitur ewlieni ta 'soluzzjonijiet teknolo\u0121i\u010bi, mag\u0127ruf g\u0127as-servizzi innovattivi u avvanzati tal-IT tieg\u0127u. B\u2019enfasi ddedikata fuq soluzzjonijiet mill-aktar avvanzati, il-kumpanija tipprovdi firxa wiesg\u0127a ta\u2019 servizzi, li jvarjaw mit-trasformazzjoni di\u0121itali u \u010b-\u010bibersigurt\u00e0 sal-cloud computing u l-analitika tad-data. Fi \u0127dan il-pro\u0121ett IMPACT, Lutech huwa impenjat li jtejjeb il-fenotipar u l-utilit\u00e0 klinika ta 'mudelli preklini\u010bi. L-g\u0127an huwa li ti\u017cdied il-prevedibbilt\u00e0 tal-appro\u010b\u010bi terapewti\u010bi fl-istudji klini\u010bi u fil-\u0121estjoni tal-mard. Barra minn hekk, Lutech huwa involut b\u2019mod attiv fl-i\u017cvilupp u l-karatterizzazzjoni ta\u2019 mudelli preklini\u010bi robusti, li jikkontribwixxu g\u0127all-avvanz \u0121enerali tal-metodolo\u0121iji u l-e\u017citi tar-ri\u010berka.<\/p>\n

\n<\/div>

<\/div>
is-sit web<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div>
<\/div><\/div><\/div><\/section><\/p>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2918","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/impact-acmproject.eu\/mt\/wp-json\/wp\/v2\/pages\/2918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/impact-acmproject.eu\/mt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/impact-acmproject.eu\/mt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/impact-acmproject.eu\/mt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/impact-acmproject.eu\/mt\/wp-json\/wp\/v2\/comments?post=2918"}],"version-history":[{"count":32,"href":"https:\/\/impact-acmproject.eu\/mt\/wp-json\/wp\/v2\/pages\/2918\/revisions"}],"predecessor-version":[{"id":4057,"href":"https:\/\/impact-acmproject.eu\/mt\/wp-json\/wp\/v2\/pages\/2918\/revisions\/4057"}],"wp:attachment":[{"href":"https:\/\/impact-acmproject.eu\/mt\/wp-json\/wp\/v2\/media?parent=2918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}